select a format

Single User License
USD 2000 INR 130040
Site License
USD 4000 INR 260080
Corporate User License
USD 6000 INR 390120

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Metastatic Prostate Cancer-Pipeline Review, H2 2015

Metastatic Prostate Cancer-Pipeline Review, H2 2015


  • Products Id :- GMDHC6865IDB
  • |
  • Pages: 95
  • |
  • July 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Metastatic Prostate Cancer-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Metastatic Prostate Cancer-Pipeline Review, H2 2015', provides an overview of the Metastatic Prostate Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Metastatic Prostate Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Metastatic Prostate Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Metastatic Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Metastatic Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Metastatic Prostate Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Metastatic Prostate Cancer Overview 9

Therapeutics Development 10

Pipeline Products for Metastatic Prostate Cancer-Overview 10

Pipeline Products for Metastatic Prostate Cancer-Comparative Analysis 11

Metastatic Prostate Cancer-Therapeutics under Development by Companies 12

Metastatic Prostate Cancer-Therapeutics under Investigation by Universities/Institutes 14

Metastatic Prostate Cancer-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Metastatic Prostate Cancer-Products under Development by Companies 18

Metastatic Prostate Cancer-Products under Investigation by Universities/Institutes 19

Metastatic Prostate Cancer-Companies Involved in Therapeutics Development 20

Actinium Pharmaceuticals, Inc. 20

Camurus AB 21

Dongkook Pharmaceutical Co., Ltd. 22

Eli Lilly and Company 23

EntreChem, S.L. 24

Johnson & Johnson 25

MedImmune, LLC 26

MEI Pharma, Inc. 27

Merck & Co., Inc. 28

OncoMax 29

OXiGENE, Inc. 30

Progenics Pharmaceuticals, Inc. 31

ValiRx Plc 32

Metastatic Prostate Cancer-Therapeutics Assessment 33

Assessment by Monotherapy Products 33

Assessment by Target 34

Assessment by Mechanism of Action 36

Assessment by Route of Administration 38

Assessment by Molecule Type 40

Drug Profiles 42

abiraterone acetate-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Actimab-P-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

AST-VAC-1-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

CADD-522-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Cell Therapy to Target PSMA for Metastatic Prostate Cancer-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

EC-7073-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

HepIn-13-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

KGP-94-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

landogrozumab-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

leuprolide acetate-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

MEDI-6469-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

MIP-1095-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

MVI-118-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

OMRCA-01-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

pracinostat-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Recombinant Protein for Oncology-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

triptorelin pamoate-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Vaccine For Oncolytic Newcastle Disease Virus-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

VAL-201-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

vorinostat-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Metastatic Prostate Cancer-Recent Pipeline Updates 72

Metastatic Prostate Cancer-Dormant Projects 84

Metastatic Prostate Cancer-Discontinued Products 86

Metastatic Prostate Cancer-Product Development Milestones 87

Featured News & Press Releases 87

Jun 01, 2015: Cleveland Clinic Researcher Discovers Metabolite of Prostate Cancer Drug more Effective at Treating Aggressive Tumors 87

Mar 27, 2014: OXiGENE Announces Presentation of Preclinical Abstracts at 2014 AACR Conference 87

Feb 06, 2014: ZYTIGA Now Reimbursed in Qubec for Use Prior to Chemotherapy in Men with Metastatic Prostate Cancer 88

Nov 21, 2013: ZYTIGA Now Available for Men with Metastatic Prostate Cancer in British Columbia Prior to Chemotherapy 89

May 29, 2013: Janssen's Zytiga Receives New Indication Approval From Health Canada For Treatment Of Metastatic Prostate Cancer 89

Jun 02, 2012: Zytiga's Phase III Results Show Significant Improvement In Radiographic Progression-Free Survival And Trend For Increased Overall Survival In Metastatic Prostate Cancer Patients 90

May 16, 2012: J&J's ZYTIGA Now Available For Eligible Patients In Nova Scotia, Newfoundland And Labrador For Prostate Cancer 91

Mar 04, 2005: Geron Announces Publication Of Phase 1-2 Telomerase Vaccine Study Results In Patients With Metastatic Prostate Cancer 92

Appendix 94

Methodology 94

Coverage 94

Secondary Research 94

Primary Research 94

Expert Panel Validation 94

Contact Us 94

Disclaimer 95

List of Tables

Number of Products under Development for Metastatic Prostate Cancer, H2 2015 10

Number of Products under Development for Metastatic Prostate Cancer-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 13

Number of Products under Investigation by Universities/Institutes, H2 2015 14

Comparative Analysis by Late Stage Development, H2 2015 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Development, H2 2015 17

Products under Development by Companies, H2 2015 18

Products under Investigation by Universities/Institutes, H2 2015 19

Metastatic Prostate Cancer-Pipeline by Actinium Pharmaceuticals, Inc., H2 2015 20

Metastatic Prostate Cancer-Pipeline by Camurus AB, H2 2015 21

Metastatic Prostate Cancer-Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2015 22

Metastatic Prostate Cancer-Pipeline by Eli Lilly and Company, H2 2015 23

Metastatic Prostate Cancer-Pipeline by EntreChem, S.L., H2 2015 24

Metastatic Prostate Cancer-Pipeline by Johnson & Johnson, H2 2015 25

Metastatic Prostate Cancer-Pipeline by MedImmune, LLC, H2 2015 26

Metastatic Prostate Cancer-Pipeline by MEI Pharma, Inc., H2 2015 27

Metastatic Prostate Cancer-Pipeline by Merck & Co., Inc., H2 2015 28

Metastatic Prostate Cancer-Pipeline by OncoMax, H2 2015 29

Metastatic Prostate Cancer-Pipeline by OXiGENE, Inc., H2 2015 30

Metastatic Prostate Cancer-Pipeline by Progenics Pharmaceuticals, Inc., H2 2015 31

Metastatic Prostate Cancer-Pipeline by ValiRx Plc, H2 2015 32

Assessment by Monotherapy Products, H2 2015 33

Number of Products by Stage and Target, H2 2015 35

Number of Products by Stage and Mechanism of Action, H2 2015 37

Number of Products by Stage and Route of Administration, H2 2015 39

Number of Products by Stage and Molecule Type, H2 2015 41

Metastatic Prostate Cancer Therapeutics-Recent Pipeline Updates, H2 2015 72

Metastatic Prostate Cancer-Dormant Projects, H2 2015 84

Metastatic Prostate Cancer-Dormant Projects (Contd..1), H2 2015 85

Metastatic Prostate Cancer-Discontinued Products, H2 2015 86

List of Figures

Number of Products under Development for Metastatic Prostate Cancer, H2 2015 10

Number of Products under Development for Metastatic Prostate Cancer-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Number of Products under Investigation by Universities/Institutes, H2 2015 14

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Products, H2 2015 17

Assessment by Monotherapy Products, H2 2015 33

Number of Products by Top 10 Targets, H2 2015 34

Number of Products by Stage and Top 10 Targets, H2 2015 34

Number of Products by Top 10 Mechanism of Actions, H2 2015 36

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 36

Number of Products by Top 10 Routes of Administration, H2 2015 38

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 38

Number of Products by Top 10 Molecule Types, H2 2015 40

Number of Products by Stage and Top 10 Molecule Types, H2 2015 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Actinium Pharmaceuticals, Inc.

Camurus AB

Dongkook Pharmaceutical Co., Ltd.

Eli Lilly and Company

EntreChem, S.L.

Johnson & Johnson

MedImmune, LLC

MEI Pharma, Inc.

Merck & Co., Inc.

OncoMax

OXiGENE, Inc.

Progenics Pharmaceuticals, Inc.

ValiRx Plc

Metastatic Prostate Cancer Therapeutic Products under Development, Key Players in Metastatic Prostate Cancer Therapeutics, Metastatic Prostate Cancer Pipeline Overview, Metastatic Prostate Cancer Pipeline, Metastatic Prostate Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com